4//SEC Filing
Kariv Tomer 4
Accession 0001209191-22-059051
CIK 0001664710other
Filed
Nov 29, 7:00 PM ET
Accepted
Nov 30, 4:38 PM ET
Size
18.2 KB
Accession
0001209191-22-059051
Insider Transaction Report
Form 4
Kariv Tomer
Director10% Owner
Transactions
- Exercise of In-Money
Common Stock
2022-11-29$0.00/sh−3,539$0→ 2,284,612 total(indirect: See footnote) - Exercise of In-Money
Common Stock
2022-11-29$0.00/sh−1,914$0→ 1,226,412 total(indirect: See footnote) - Exercise of In-Money
Call Options (obligation to sell)
2022-11-29−1,723→ 0 total(indirect: See footnote)Exercise: $0.00Exp: 2023-10-07→ Common Stock (1,723 underlying) - Exercise of In-Money
Common Stock
2022-11-29$0.00/sh−1,723$0→ 1,121,045 total(indirect: See footnote) - Exercise of In-Money
Call Options (obligation to sell)
2022-11-29−3,539→ 0 total(indirect: See footnote)Exercise: $0.00Exp: 2023-10-07→ Common Stock (3,539 underlying) - Exercise of In-Money
Call Options (obligation to sell)
2022-11-29−1,914→ 0 total(indirect: See footnote)Exercise: $0.00Exp: 2023-10-07→ Common Stock (1,914 underlying)
Footnotes (5)
- [F1]Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder.
- [F2]The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F3]The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F4]The securities are held by China IV. Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F5]Fully vested and exercisable.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001568077
Filing Metadata
- Form type
- 4
- Filed
- Nov 29, 7:00 PM ET
- Accepted
- Nov 30, 4:38 PM ET
- Size
- 18.2 KB